Evidence map›Paper›PMID 40960629›Full record

ArticleActa diabetologica2025

Retinopathy and nephropathy in type 1 diabetes: role of HbA1c and blood pressure variability.

Pavel Fatulla, Johnny Ludvigsson, Henrik Imberg, Thomas Nyström, Marcus Lind

Abstract read
In one paragraph

Article in Acta diabetologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Pavel FatullaDepartment of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Johnny LudvigssonCrown Princess Victoria Children's Hospital, Division of Paediatrics, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
Henrik ImbergDepartment of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Thomas NyströmDepartment of Clinical Science and Education, Internal Medicine, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden.
Marcus LindDepartment of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. marcus.lind@gu.se.ORCID http://orcid.org/0000-0002-3796-9283

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsTo examine the association between within-person variability in glycated hemoglobin A1c (HbA1c) and blood pressure (BP) with retinopathy and nephropathy in type 1 diabetes (T1D).

methodsThis nationwide cohort included 9,358 individuals from the Swedish National Diabetes Register with T1D <5 years at inclusion (1998-2017) and ≥8 years follow-up. Variability in HbA1c, systolic BP (SBP), and diastolic BP (DBP) was calculated as updated SDs. Associations with microvascular complications were analyzed using logistic regression with generalized estimating equations, adjusted for demographic and clinical covariates.

resultsMean age at inclusion was 14.2 years, mean diabetes duration 1.2 years, and 44% were female. Over 10.7 years' follow-up, retinopathy developed in 33% and nephropathy in 9.3%. SBP variability was significantly associated with pre-proliferative or proliferative retinopathy (aOR 1.13, 95% CI 1.00-1.27) and proliferative retinopathy/ laser photocoagulation (1.23, 1.04-1.45), as well as with any albuminuria (1.15, 1.08-1.23) and macroalbuminuria (1.29, 1.15-1.45). DBP variability was associated with any albuminuria (1.11, 1.03-1.19) and macroalbuminuria (1.28, 1.10-1.50). HbA1c variability was associated with any retinopathy (1.14, 1.08-1.20) and any albuminuria (1.12, 1.03-1.21).

conclusionsBeyond mean levels, higher variability in HbA1c and BP is associated with retinopathy and nephropathy. Stable BP control in patients with established retinopathy may be important to prevent progression to sight-threatening stages.

Indexed as

Blood PressureDiabetes Mellitus, Type 1Diabetic NephropathiesDiabetic RetinopathyGlycated HemoglobinAdolescentAdultChildCohort StudiesFemaleHumansMaleSwedenYoung AdultGlycated Hemoglobinhemoglobin A1c protein, humanBlood pressure variabilityHbA1c variabilityMicrovascular complicationsNephropathyRetinopathyType 1 diabetes

Identifiers

PMID40960629
PMCPMC12727752

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.